Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer

Takayuki Iwamoto, Giampaolo Bianchini, Daniel Booser, Yuan Qi, Charles Coutant, Christine Ya-Hui Shiang, Libero Santarpia, Junji Matsuoka, Gabriel N. Hortobagyi, William Fraser Symmans, Frankie A. Holmes, Joyce O'Shaughnessy, Beth Hellerstedt, John Pippen, Fabrice Andre, Richard Simon, Lajos Pusztai

Research output: Contribution to journalArticle

Abstract

Background We hypothesized that distinct biological processes might be associated with prognosis and chemotherapy sensitivity in the different types of breast cancers. Methods We performed gene set analyses with BRB-ArrayTools statistical software including 2331 functionally annotated gene sets (ie, lists of genes that correspond to a particular biological pathway or biochemical function) assembled from Ingenuity Pathway Analysis and Gene Ontology databases corresponding to almost all known biological processes. Gene set analysis was performed on gene expression data from three cohorts of 234, 170, and 175 patients with HER2-normal lymph node-negative breast cancer who received no systemic adjuvant therapy to identify gene sets associated prognosis and three additional cohorts of 198, 85, and 62 patients with HER2-normal stage I-III breast cancer who received preoperative chemotherapy to identify gene sets associated with pathological complete response to therapy. These analyses were performed separately for estrogen receptor (ER)-positive and ER-negative breast cancers. Interaction between gene sets and survival and treatment response by breast cancer subtype was assessed in individual datasets and also in pooled datasets. Statistical significance was estimated with permutation test. All statistical tests were two-sided. Results For ER-positive cancers, from 370 to 434 gene sets were associated with prognosis (P ≤. 05) and from 209 to 267 gene sets were associated with chemotherapy response in analysis by individual dataset. For ER-positive cancers, 131 gene sets were associated with prognosis and 69 were associated with pathological complete response (P ≤.001) in pooled analysis. Increased expression of cell cycle-related gene sets was associated with poor prognosis, and B-cell immunity-related gene sets were associated with good prognosis. For ER-negative cancers, from 175 to 288 gene sets were associated with prognosis and from 212 to 285 gene sets were associated with chemotherapy response. In pooled analyses of ER-negative cancers, 14 gene sets were associated with prognosis and 23 were associated with response. Gene sets involved in sphingolipid and glycolipid metabolism were associated with better prognosis and those involved in base excision repair, cell aging, and spindle microtubule regulation were associated with chemotherapy response. Conclusion Different biological processes were associated with prognosis and chemotherapy response in ER-positive and ER-negative breast cancers.

Original languageEnglish
Pages (from-to)264-272
Number of pages9
JournalJournal of the National Cancer Institute
Volume103
Issue number3
DOIs
Publication statusPublished - Feb 2 2011

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Iwamoto, T., Bianchini, G., Booser, D., Qi, Y., Coutant, C., Ya-Hui Shiang, C., Santarpia, L., Matsuoka, J., Hortobagyi, G. N., Symmans, W. F., Holmes, F. A., O'Shaughnessy, J., Hellerstedt, B., Pippen, J., Andre, F., Simon, R., & Pusztai, L. (2011). Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. Journal of the National Cancer Institute, 103(3), 264-272. https://doi.org/10.1093/jnci/djq524